文献速递膀胱癌与上尿路尿路上皮癌

膀胱影像报告和数据系统(VI-RADS)评分后光动力经尿道切除非肌层浸润性膀胱癌对比白光常规电切及二次电切:「CUT-less」随机试验方案

VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.
PubMed 文献 · BJU Int · 2024-10-13

CUT-less试验为单中心、非劣效性、IV期、开放标签、1:1随机对照试验,计划3年内入组327例中高危非肌层浸润性膀胱癌(NMIBC)患者。试验比较标准治疗(初次白光经尿道膀胱肿瘤电切术(TURBT)后行二次白光Re-TURBT)与试验组(初次光动力诊断(PDD)-TURBT并省略Re-TURBT),主要终点为4.5个月内膀胱癌复发比例,以评估术前VI-RADS评分1和/或2分的患者能否安全避免Re-TURBT。

要点

  • CUT-less试验旨在联合VI-RADS术前分期与PDD术中增强能力,重新定义二次电切(Re-TURBT)指征。
  • 主要终点为4.5个月内膀胱癌复发比例,评估VI-RADS评分1和/或2分患者避免Re-TURBT的非劣效性。
  • 计划入组327例中高危NMIBC患者,随机1:1接受标准治疗或试验组(PDD-TURBT省略Re-TURBT)。

核心结论

  • CUT-less试验旨在联合VI-RADS术前分期准确性与PDD术中增强能力,克服初次TURBT的陷阱,从而可能重新定义Re-TURBT指征。

研究设计与样本

  • 单中心、非劣效性、IV期、开放标签、随机对照试验,按1:1比例随机分组。
  • 计划在3年期间入组327例中高危NMIBC患者,这些患者按EAU指南为Re-TURBT候选者。
  • 所有患者术前均接受膀胱多参数磁共振成像(mpMRI)并确定VI-RADS评分。

主要发现

  • 主要终点为4.5个月内(即首次随访膀胱镜检查发现的任何「早期」复发)标准治疗组与试验组之间膀胱癌复发的相对比例。
  • 次要终点包括4.5个月随访后发现的晚期膀胱癌复发和/或进展的相对比例。
  • 次要终点还包括健康相关生活质量(HRQoL)结局和健康经济学成本-效益分析。

关键数值与推荐

  • 术前VI-RADS评分1和/或2分(即肌层浸润性膀胱癌(MIBC)可能性极低和低)的患者可能通过接受初次PDD-TURBT安全避免Re-TURBT。
  • 标准治疗组接受初次白光TURBT后行二次白光Re-TURBT;试验组接受初次PDD-TURBT并省略Re-TURBT。
  • 两组均按风险调整方案接受辅助膀胱内治疗和监测。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A second transurethral resection of bladder tumour (Re-TURBT) is recommended by European Association of Urology (EAU) Guidelines on non-muscle-invasive bladder cancers (NMIBCs) due to the risk of understaging and/or persistent disease following the primary resection. However, in many cases this may be unnecessary, potentially harmful, and significantly expensive constituting overtreatment. The CUT-less trial aims to combine the preoperative staging accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) and the intraoperative enhanced ability of photodynamic diagnosis (PDD) to overcome the primary TURBT pitfalls thus potentially re-defining criteria for Re-TURBT indications. STUDY DESIGN: Single-centre, non-inferiority, phase IV, open-label, randomised controlled trial with 1:1 ratio. ENDPOINTS: The primary endpoint is short-term BC recurrence between the study arms to assess whether patients preoperatively categorised as VI-RADS Score 1 and/or Score 2 (i.e., very-low and low likelihood of MIBC) could safely avoid Re-TURBT by undergoing primary PDD-TURBT. Secondary endpoints include mid- and long-term BC recurrences and progression (i-ii). Also, health-related quality of life (HRQoL) outcomes (iii) and health-economic cost-benefit analysis (iv) will be performed. PATIENTS AND METHODS: All patients will undergo preoperative Multiparametric Magnetic Resonance Imaging of the bladder with VI-RADS score determination. A total of 327 patients with intermediate-/high-risk NMIBCs, candidate for Re-TURBT according to EAU Guidelines, will be enrolled over a 3-year period. Participants will be randomised (1:1 ratio) to either standard of care (SoC), comprising primary white-light (WL) TURBT followed by second WL Re-TURBT; or the Experimental arm, comprising primary PDD-TURBT and omitting Re-TURBT. Both groups will receive adjuvant intravesical therapy and surveillance according to risk-adjusted schedules. Measure of the primary outcome will be the relative proportion of BC recurrences between the SoC and Experimental arms within 4.5 months (i.e., any 'early' recurrence detected at first follow-up cystoscopy). Secondary outcomes measures will be the relative proportion of late BC recurrences and/or BC progression detected after 4.5 months follow-up. Additionally, we will compute the HRQoL variation from NMIBC questionnaires modelled over a patient lifetime horizon and the health-economic analyses including a short-term cost-benefit assessment of incremental costs per Re-TURBT avoided and a longer-term cost-utility per quality-adjusted life year gained using 2-year clinical outcomes to drive a lifetime model across the two arms of treatment. TRIAL REGISTRATION: ClinicalTrial.gov identifier (ID): NCT05962541; European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) ID: 2023-507307-64-00.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Del Giudice F, Vestri A, Fegatelli DA, et al. VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol. BJU Int. 2024. PMID: 39397266. doi:10.1111/bju.16531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。